These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 18520982

  • 1. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
    Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P.
    Clin Neuropharmacol; 2008; 31(3):151-66. PubMed ID: 18520982
    [Abstract] [Full Text] [Related]

  • 2. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 3. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H.
    Neurology; 2005 Jan 25; 64(2):216-23. PubMed ID: 15668416
    [Abstract] [Full Text] [Related]

  • 4. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A, Devos D, Seguy D, Dujardin K, Destée A, Defebvre L.
    Rev Neurol (Paris); 2009 Jan 25; 165(8-9):718-27. PubMed ID: 19150100
    [Abstract] [Full Text] [Related]

  • 5. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR.
    Mov Disord; 2009 Jul 30; 24(10):1468-74. PubMed ID: 19425079
    [Abstract] [Full Text] [Related]

  • 6. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.
    Hauser RA, McDermott MP, Messing S.
    Arch Neurol; 2006 Dec 30; 63(12):1756-60. PubMed ID: 17172616
    [Abstract] [Full Text] [Related]

  • 7. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM.
    Clin Neuropharmacol; 2008 Dec 30; 31(2):63-73. PubMed ID: 18382177
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study.
    Stocchi F, Vacca L, Ruggieri S, Olanow CW.
    Arch Neurol; 2005 Jun 30; 62(6):905-10. PubMed ID: 15956161
    [Abstract] [Full Text] [Related]

  • 10. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G.
    Mov Disord; 2007 Jun 15; 22(8):1145-9. PubMed ID: 17661426
    [Abstract] [Full Text] [Related]

  • 11. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D.
    Expert Rev Neurother; 2006 Oct 15; 6(10):1403-11. PubMed ID: 17078781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M, Swinn L, Watt H, Bhatia K, Quinn N, Lees AJ.
    Mov Disord; 2005 Feb 15; 20(2):151-7. PubMed ID: 15390035
    [Abstract] [Full Text] [Related]

  • 14. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
    Castaño B, Mateo D, Giménez-Roldán S.
    Neurologia; 2007 Apr 15; 22(3):133-7. PubMed ID: 17364250
    [Abstract] [Full Text] [Related]

  • 15. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov 15; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH, Klasser M, Reichmann H.
    Fortschr Neurol Psychiatr; 2008 Oct 15; 76(10):594-9. PubMed ID: 18833504
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.